MedTrace Logo

Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy of Different Tetracycline Doses and Frequencies.

NCT05432115 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 407

Last updated 2023-01-31

No results posted yet for this study

Summary

The researchers collect H.pylori-positive patients who need rescue therapy from the outpatient clinic. The subjects were randomized to receive a dose and frequency of tetracycline 500mg tid or qid of bismuth quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates and patient compliance of each group.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Tetracyclin

Amoxicillin 1000mg bid +Tetracycline 500mg tid/qid +Bismuth+Esomeprazole 40mg bid

Sponsors & Collaborators

  • Peking University Care Luzhong Hospital

    collaborator OTHER

  • Zibo Central Hospital

    collaborator OTHER_GOV

  • Zhengzhou Central Hospital

    collaborator OTHER

  • Taierzhuang District People's Hospital

    collaborator OTHER

  • Yuncheng Traditional Chinese Medicine Hospital

    collaborator OTHER

  • Shandong University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-25
Primary Completion
2023-08-31
Completion
2023-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05432115 on ClinicalTrials.gov